162 related articles for article (PubMed ID: 22033492)
1. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
3. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
4. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes.
Cocco L; Finelli C; Mongiorgi S; Clissa C; Russo D; Bosi C; Quaranta M; Malagola M; Parisi S; Stanzani M; Ramazzotti G; Mariani GA; Billi AM; Manzoli L; Follo MY
J Leukoc Biol; 2015 Nov; 98(5):769-80. PubMed ID: 25977289
[TBL] [Abstract][Full Text] [Related]
5. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378
[TBL] [Abstract][Full Text] [Related]
6. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Inositide Signaling Via Phospholipase C.
Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
[TBL] [Abstract][Full Text] [Related]
9. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
Cappellini A; Mongiorgi S; Finelli C; Fazio A; Ratti S; Marvi MV; Curti A; Salvestrini V; Pellagatti A; Billi AM; Suh PG; McCubrey JA; Boultwood J; Manzoli L; Cocco L; Follo MY
FASEB J; 2020 Nov; 34(11):15400-15416. PubMed ID: 32959428
[TBL] [Abstract][Full Text] [Related]
11. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
[TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
13. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D
Clin Cancer Res; 2013 Jun; 19(12):3297-308. PubMed ID: 23596104
[TBL] [Abstract][Full Text] [Related]
15. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Bosi C; Martinelli G; Mongiorgi S; Baccarani M; Manzoli L; Blalock WL; Martelli AM; Cocco L
Leukemia; 2008 Jan; 22(1):198-200. PubMed ID: 17625605
[No Abstract] [Full Text] [Related]
16. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
17. Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation.
Mongiorgi S; Follo MY; Yang YR; Ratti S; Manzoli L; McCubrey JA; Billi AM; Suh PG; Cocco L
Curr Pharm Des; 2016; 22(16):2345-8. PubMed ID: 26916022
[TBL] [Abstract][Full Text] [Related]
18. Physiology and pathology of nuclear phospholipase C β1.
Cocco L; Follo MY; Faenza I; Fiume R; Ramazzotti G; Weber G; Martelli AM; Manzoli FA
Adv Enzyme Regul; 2011; 51(1):2-12. PubMed ID: 21035488
[TBL] [Abstract][Full Text] [Related]
19. Nuclear inositide signaling in myelodysplastic syndromes.
Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
[TBL] [Abstract][Full Text] [Related]
20. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
